

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 7/24/1973  
**Sex:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**Gamma-Hydroxybutyric Acid (GHB), Serum or Plasma - Screen with Reflex to Confirmation/Quantitation**

ARUP test code 0091193

Gamma-Hydroxybutyric Acid Screen, S/P

See note mcg/mL  
Plasma  
Reporting Limit: 5.0 mcg/mL  
Synonym(s): GHB; Gamma-Hydroxybutyrate  
Comment:  
Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).  
Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)  
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.  
Testing performed at NMS Labs, Inc.  
200 Welsh Road  
Horsham, PA 19044-2208  
CLIA 39D0197898

**Gamma-Hydroxybutyric Acid (GHB) Confirmation, Serum or Plasma**

ARUP test code 3000194

Gamma-Hydroxybutyric Acid Confirmation

320 mcg/mL  
Plasma  
Reporting Limit: 50 mcg/mL  
Synonym(s): GHB; Gamma-Hydroxybutyrate  
Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.  
The following effects have been generally associated with the corresponding blood concentrations:  
>260 mcg/mL: Deep sleep/coma  
150 - 260 mcg/mL: Moderate sleep  
52 - 150 mcg/mL: Light sleep  
< 52 mcg/mL: wakefulness  
Responses are variable and may differ even within the same individual.  
The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.  
Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)  
This test was developed and its performance

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.  
Testing performed at NMS Labs, Inc.  
200 Welsh Road  
Horsham, PA 19044-2208  
CLIA 39D0197898

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Gamma-Hydroxybutyric Acid Screen, S/P	22-001-104687	1/1/2022 9:31:00 AM	1/5/2022 11:51:05 AM	1/18/2022 12:15:00 PM
Gamma-Hydroxybutyric Acid Confirmation	22-001-104687	1/1/2022 9:31:00 AM	1/13/2022 1:03:42 AM	1/18/2022 12:15:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 22-001-104687  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 10/19/2022 7:20:32 AM